Table 4. Relationship between CLDN4 expression and clinicopathological parameters in CDX2-positive and -negative gastric cancer.
| CDX2(+)1 | CDX2(–)1 | |||||
|---|---|---|---|---|---|---|
| n | Expression index2 | P3 | n | Expression index2 | P3 | |
| Parameters4 | ||||||
| pT | ||||||
| 1–2 | 82 | 182 ± 10 | 56 | 178 ± 11 | ||
| 3–4 | 34 | 179 ± 14 | NS | 20 | 99 ± 15 | < 0.001 |
| pN | ||||||
| 0 | 99 | 177 ± 9 | 69 | 159 ± 10 | ||
| 1–3 | 17 | 202 ± 20 | NS | 7 | 141 ± 38 | NS |
| pStage | ||||||
| I | 75 | 183 ± 10 | 52 | 172 ± 11 | ||
| II–IV | 41 | 177 ± 13 | NS | 24 | 126 ± 17 | < 0.05 |
1CDX2 was evaluated as positive by immunoreactivity in 20% or more nuclei of 1000 observed nuclei.
2Claudin-4 expression index was calculated as the staining strength score multiplied by the staining area.
3P value was calculated by ordinary ANOVA test. NS, not significant.
4pT1–2, tumor confined within the submucosa or tumor invades the muscularis propria; pT3–4, tumor invades the subserosa or tumor invasion is contiguous to or exposed beyond the serosa or tumor invades adjacent structures; pN0, no regional lymph node metastasis; pN1-3, metastasis in 1 or more regional lymph nodes; pStage I, pT1 and pN0 or pN1, or pT2 and pN0, pStage II–IV, all cases other than pStage I [34].